ArticlePloS one2014
Reduction of Campylobacter jejuni in broiler chicken by successive application of group II and group III phages.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 96 citations in OpenAlex.
- A review on phytochemical and bacteriophage based therapeutic strategies for the management of Brucellosis.Frontiers in veterinary science · 2026Review
- Regulatory Landscape and the Potential of Bacteriophage Applications in the United States' Food Industry.Journal of food protection · 2025Review
- Characterization and genomic analysis of aFrontiers in microbiology · 2025Article
- An insight into the applications of bacteriophages against food-borne pathogens.Journal of food science and technology · 2025Review
- A blueprint for broadly effective bacteriophage-antibiotic cocktails against bacterial infections.Nature communications · 2024Article
- A broad host phage, CP6, for combating multidrug-resistant Campylobacter prevalent in poultry meat.Poultry science · 2024Article
- Investigating bacteriophages as a novel multiple-hurdle measure against Campylobacter: field trials in commercial broiler plants.Scientific reports · 2024Article
- A hybrid receptor binding protein enables phage F341 infection ofFrontiers in microbiology · 2024Article
- Potential application of phage vB_EfKS5 to control Enterococcus faecalis and its biofilm in food.AMB Express · 2023Article
- Bacteriophage cocktail application for Campylobacter mitigation - from in vitro to in vivo.BMC microbiology · 2023Article
- Bacteriophages and food safety: An updated overview.Food science & nutrition · 2023Review
- Bacteriophages in Infectious Diseases and Beyond-A Narrative Review.Antibiotics (Basel, Switzerland) · 2023Review
- Natural Killers: Opportunities and Challenges for the Use of Bacteriophages in Microbial Food Safety from the One Health Perspective.Foods (Basel, Switzerland) · 2023Review
- Intervention Strategies to ControlMicroorganisms · 2023Review
- Recent trends in the use of bacteriophages as replacement of antimicrobials against food-animal pathogens.Frontiers in veterinary science · 2023Review
- An overview of the use of bacteriophages in the poultry industry: Successes, challenges, and possibilities for overcoming breakdowns.Frontiers in microbiology · 2023Review
- Bacteriophages as Biocontrol Agents in Livestock Food Production.Microorganisms · 2022Review
- Bacteriophages and Food Production: Biocontrol and Bio-Preservation Options for Food Safety.Antibiotics (Basel, Switzerland) · 2022Review
- From Farm to Fork:Viruses · 2022Review
- Isolation, Characterization, and Genomic Analysis of Three NovelMicroorganisms · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBacteriophage treatment is a promising tool to reduce Campylobacter in chickens. Several studies have been published where group II or group III phages were successfully applied. However, these two groups of phages are different regarding their host ranges and host cell receptors. Therefore, a concerted activity of group II and group III phages might enhance the efficacy of a treatment and decrease the number of resistant bacteria.
resultsIn this study we have compared the lytic properties of some group II and group III phages and analysed the suitability of various phages for a reduction of C. jejuni in broiler chickens. We show that group II and group III phages exhibit different kinetics of infection. Two group III and one group II phage were selected for animal experiments and administered in different combinations to three groups of chickens, each containing ten birds. While group III phage CP14 alone reduced Campylobacter counts by more than 1 log10 unit, the concomitant administration of a second group III phage (CP81) did not yield any reduction, probably due to the development of resistance induced by this phage. One group of chickens received phage CP14 and, 24 hours later, group II phage CP68. In this group of animals, Campylobacter counts were reduced by more than 3 log10 units.
conclusionThe experiments illustrated that Campylobacter phage cocktails have to be carefully composed to achieve the best results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.